The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.

Leading AI labs, executives, and scientists are sending a letter to lawmakers urging them to improve tracking of synthetic DNA sequences that could be used for bioweapons.